Eli Lilly and Company (NYSE:LLY) Shares Purchased by Oliver Lagore Vanvalin Investment Group

Oliver Lagore Vanvalin Investment Group raised its stake in Eli Lilly and Company (NYSE:LLY) by 27.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 387 shares of the company’s stock after acquiring an additional 84 shares during the quarter. Oliver Lagore Vanvalin Investment Group’s holdings in Eli Lilly and Company were worth $226,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of LLY. Fairfield Bush & CO. acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $107,000. Roundview Capital LLC lifted its position in shares of Eli Lilly and Company by 2.6% during the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after buying an additional 53 shares in the last quarter. Merit Financial Group LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $210,000. NewEdge Advisors LLC lifted its position in shares of Eli Lilly and Company by 9.9% during the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after buying an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $561,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Truist Financial reiterated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $745.95 on Friday. The stock has a market cap of $708.77 billion, a PE ratio of 128.61, a P/E/G ratio of 1.64 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a twelve month low of $367.35 and a twelve month high of $800.78. The stock has a fifty day simple moving average of $764.24 and a 200-day simple moving average of $658.28.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.09 EPS. Equities analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.